NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the fourth quarter and year ended December 31, 2008. Celldex reported a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008 compared to a net loss of $4.2 million, or $0.51 per share, for the fourth quarter of 2007. For the year ended December 31, 2008, Celldex reported a net loss of $47.5 million, or $3.34 per share, compared to a net loss of $15.1 million, or $1.81 per share, for the year ended December 31, 2007. On March 7, 2008, privately-held Celldex Therapeutics, Inc. completed its merger with a wholly-owned subsidiary of AVANT Immunotherapeutics and, effective October 1, 2008, AVANT changed its name to Celldex Therapeutics, Inc.
